Related Experiment Videos
Mechanisms underlying lack of insulin-like growth factor-binding protein-3 expression in non-small-cell lung cancer
Yoon Soo Chang1, Luo Wang, Young-Ah Suh
1Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Box 432, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Abstract:
Expression of insulin-like growth factor-binding protein-3, which (IGFBP-3) inhibits the proliferation of non-small-cell lung cancer (NSCLC) cells by inducing apoptosis, is lost in about half of stage I NSCLC cases. Since promoter methylation can silence gene expression, we investigated whether hypermethylation of the IGFBP-3 promoter is involved in loss of IGFBP-3 expression in NSCLC. We found the IGFBP-3 promoter to be methylated in seven of 13 NSCLC cell lines and in 16 of 23, seven of 9, eight of 11, and six of six tumor specimens from patients with stage I, II, III, and IV NSCLC, respectively. Methylation status correlated with IGFBP-3 mRNA and protein levels in a subset of NSCLC cell lines tested in our study. However, treatment with 5'-aza-2'-deoxycytidine (5'-aza-dC) restored IGFBP-3 expression in four of seven NSCLC cell lines with the methylated promoter, suggesting that multiple mechanisms regulate IGFBP-3 expression in NSCLC. Gel shift and chromatin immunoprecipitation assays showed that methylation of the Sp-1/Sp-3-binding element in the IGFBP-3 promoter influenced the binding of Sp-1, methyl-CpG-binding protein-2 (MeCP2), and histone deacetylase (HDAC). A luciferase construct expressing IGFBP-3 promoter in which the Sp-1/Sp-3 binding element was methylated showed significantly reduced transcriptional activity. The reduction in promoter activity was further suppressed by overexpression of MeCP2, which was rescued by 5'-aza-dC. Thus interference with Sp-1 transactivation by MeCP2 may contribute to the transcriptional defect of IGFBP-3 expression in NSCLC cells with methylated promoter.
Insights
Hypermethylation of the IGFBP-3 promoter silences gene expression in non-small-cell lung cancer (NSCLC). This epigenetic silencing, mediated by Sp-1/Sp-3 and MeCP2, contributes to tumor progression and can be reversed by demethylating agents.
Area of Science:
- Oncology
- Molecular Biology
- Epigenetics
Background:
- Insulin-like growth factor-binding protein-3 (IGFBP-3) inhibits non-small-cell lung cancer (NSCLC) cell proliferation by inducing apoptosis.
- Loss of IGFBP-3 expression is observed in approximately half of stage I NSCLC cases.
Purpose of the Study:
- To investigate the role of IGFBP-3 promoter hypermethylation in the loss of IGFBP-3 expression in NSCLC.
- To elucidate the molecular mechanisms underlying IGFBP-3 silencing in NSCLC.
Main Methods:
- Analysis of IGFBP-3 promoter methylation status in NSCLC cell lines and tumor specimens.
- Treatment of NSCLC cell lines with 5'-aza-2'-deoxycytidine (5'-aza-dC) to assess promoter demethylation and gene expression restoration.
- Gel shift and chromatin immunoprecipitation assays to study protein-DNA interactions at the IGFBP-3 promoter.
- Luciferase reporter assays to evaluate the impact of promoter methylation on transcriptional activity.
Main Results:
- IGFBP-3 promoter hypermethylation was detected in a significant proportion of NSCLC cell lines and tumors across all stages.
- Methylation status correlated with reduced IGFBP-3 mRNA and protein levels.
- 5'-aza-dC treatment partially restored IGFBP-3 expression in some cell lines, indicating epigenetic regulation.
- Methylation of the Sp-1/Sp-3 binding element affected the binding of Sp-1, MeCP2, and HDAC.
- MeCP2 overexpression further suppressed the transcriptional activity of the methylated IGFBP-3 promoter.
Conclusions:
- IGFBP-3 promoter hypermethylation is a common mechanism contributing to IGFBP-3 silencing in NSCLC.
- MeCP2-mediated interference with Sp-1 transactivation plays a role in the transcriptional defect of IGFBP-3 in NSCLC cells with a methylated promoter.
- These findings highlight the potential of epigenetic therapies targeting promoter methylation for NSCLC treatment.
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Regulation of Angiogenesis and Blood Supply
Abnormal Proliferation